Catto, J., Tran, B., Rouprêt, M., Gschwend, J., Loriot, Y., Nishiyama, H., . . . Steinberg, G. (2024). Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer.
Citación estilo ChicagoCatto, JWF, et al. Erdafitinib in BCG-treated High-risk Non-muscle-invasive Bladder Cancer. 2024.
Cita MLACatto, JWF, et al. Erdafitinib in BCG-treated High-risk Non-muscle-invasive Bladder Cancer. 2024.
Precaución: Estas citas no son 100% exactas.